To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Status epilepticus is defined as one seizure persisting for greater than 5 minutes, or two seizures within a 5-minute period without interval return to baseline. This condition is characterized by intractable seizure and represents a true medical emergency, as it poses a severe threat of anoxic brain injury that increases with duration of seizure. Status epilepticus has widely varied causes, including but not limited to hypoglycemia, electrolyte abnormalities, substance withdrawal, medications/toxins, new-onset primary seizure disorders, malignancy, and trauma. Following the classic primary survey, management should focus on cessation of seizure activity through administration of benzodiazepines, with progression to phenytoin/fosphenytoin and even barbiturates should seizures remain refractory. Airway protection should be actively maintained given the often-high doses of these medications. Work-up should include basic laboratory panels, including CBC, BMP, LFTs, coags, UA, serum tox, ABG, and ECG; imaging should include CXR and CT head. A thorough history should be obtained from patient/family/bystanders if possible following stabilization, and neurology consult should be considered.
This chapter presents a case of a 47-year-old male with confusion secondary to hyponatremia, caused by beer potomania (excessive beer consumption). The case highlights the approach to a patient with an altered mental status, seizures, and severe hyponatremia. The approach to diagnostic testing, stabilization, and interventions to prevent progression and deterioration to a comatose state are described.
Generalized seizures that occur in children between 6 months and 5 years of age during a febrile illness and last less than 15 minutes are known as simple febrile seizures. Children may experience a brief post-ictal period but should return to baseline fairly quickly. Children with simple febrile seizures should be given antipyretics and a careful history and physical should be performed. If a source of the fever is identified, it should be treated. Most often, children do not require blood work or a lumbar puncture in the work-up of a simple febrile seizure. If the child has returned to baseline and is well-appearing, they may be discharged home with follow-up with their primary care physician. Complex febrile seizures, in contrast, may last longer than 15 minutes, may occur several times in a short period of time, or may be focal. A more thorough work-up is often required for complex febrile seizures.
Seizure can have multiple precipitating factors. A broad initial differential diagnosis is critical to rapidly identify the underlying etiology of seizure, including hypoglycemia, hypoxemia, intracranial hemorrhage or infection, electrolyte abnormalities, withdrawal, or underlying epilepsy. One specific cause of seizure is pregnancy in the third trimester, termed eclampsia. Risk factors for eclampsia include young or old age, primigravida or nulliparity, multifetal gestations, obesity, chronic hypertension, kidney disease, and diabetes. The management of eclampsia includes magnesium sulfate and blood pressure control as needed. Magnesium sulfate can be given as a 4−6 g IV bolus, followed by a continuous infusion of 2 g per hour, with monitoring for magnesium toxicity as evidenced by loss of deep tendon reflexes, hypotension, or respiratory depression. Magnesium toxicity can be treated with calcium gluconate. Elevated blood pressure refractory to magnesium administration should be treated with antihypertensives, including intravenous labetalol or hydralazine, or oral nifedipine. Blood pressure targets are a systolic blood pressure of less than 160 mmHg and a diastolic blood pressure of less than 110 mmHg. Emergent obstetrics consultation is required, as delivery of the fetus is the only definitive treatment.
A 48-year-old male with a known history of alcohol abuse is brought in by EMS for altered mental status. Upon arrival to the ED, he is atraumatic, hypertensive, tachycardic, confused, agitated, uncooperative, and diaphoretic. Fingerstick is within normal limits. He is sedated to expedite work-up and for patient and staff safety. A “coma cocktail” is administered without adequate response. The patient subsequently develops a grand mal seizure responsive to benzodiazepines. Alcohol level is 56 and the rest of the bloodwork is unremarkable. CT head without contrast is negative for acute intracranial hemorrhage. The patient is admitted to the ICU for alcohol withdrawal seizures.
1. Pharmacologic management of active seizure in cancer patients starts with benzodiazepines, followed by levetiracetam or lacosamide load. For refractory seizures, intubate and start a benzodiazepine infusion.
2. Tailor a differential diagnosis. Determine whether the seizure was focal or generalized. Obtain a history of their treatments, medications and recent changes, preceding symptoms, and determine if there are residual symptoms or deficits.
3. New seizures in any cancer patient should prompt imaging to evaluate for structural lesion, first with non-contrast CT head followed by gadolinium-enhanced MRI. Focal seizures suggest focal causation.
4. Continuous video EEG is preferred, as shorter EEG may fail to capture non-convulsive status epilepticus (NCSE).
5. Metabolic derangements can present with seizures and is common in patients with oncologic processes. Therefore, a high degree of suspicion and low threshold for repletion of electrolytes and correction of acid-base abnormality is imperative.
Patients undergoing craniotomy experience a higher risk of seizures in the ensuing months. Consensus is lacking regarding the appropriate timeframe for safe return to driving following craniotomy in patients not otherwise limited by neurological deficits or a history of epilepsy.
Methods:
The Canadian Neurosurgery Research Collaborative (CNRC) distributed an anonymous, voluntary, electronic cross-sectional survey via SurveyMonkey to Canadian neurosurgeons. The survey comprised 16 questions designed to assess practice variations regarding recommendations for return to driving following craniotomy, stratified according to pathological diagnosis.
Results:
Forty-eight Canadian neurosurgeons responded to the survey. Driving recommendations varied greatly, with most surgeons recommending return to driving within one month of the craniotomy. The rationale behind these restrictions varied widely, consistent with the lack of evidence-based data to guide decision-making.
Conclusion:
This study emphasizes the lack of standardized practices regarding return to driving recommendations for patients undergoing craniotomy without prior seizures. Development of national return to driving guidelines would assist Canadian clinicians in making informed decisions regarding the optimal timeframe for the safe return to driving.
People living with epilepsy (PWE) experience higher rates of depression compared with the general population. Depression in PWE is associated with increased seizure burden and reduced quality of life. We aimed to examine clinical and demographic correlates of depression severity using the nine-item Patient Health Questionnaire in PWE experiencing negative health events in the past 6 months.
Aims
(a) To assess how depressive severity correlated with seizure frequency;
(b) To examine how outcomes such as quality of life are influenced by depressive severity;
(c) To investigate how demographic factors affect depressive severity.
Method
Depressive severity was defined as a score of 0–9 for no depression to mild symptoms (NMD), 10–19 for moderate depression (MOD) and 20–27 for severe depression. Continuous variables were analysed using the Kruskal–Wallis equality-of-populations rank test, and categorical variables were compared using Fisher’s exact test. Baseline data were taken from Sequential, Multiple Assignment Randomized Trial no. NCT04705441.
Results
The sample of 159 participants had a mean age of 39.46 years (s.d., 12.15), with the majority (n = 131, 82.4%) identifying as White. A total of 48% (n = 76) of participants met the criteria for NMD, 41% (n = 65) met those for MOD and 11% (n = 18) met those for severe depression. The severe depression group had significantly more seizures in the past 30 days, as well as greater perceived stigma, lower social support and lower quality of life, compared with the other groups. Race was found to correlate with depressive severity in NMD and MOD versus the severe depression group.
Conclusions
Among adults with epilepsy, depressive severity was positively correlated with seizure frequency and stigma and negatively correlated with quality of life, social support and overall functioning. These results highlight the importance of routine screening for depression, and of providing management of these symptoms in comprehensive epilepsy care.
Edited by
Rebecca Leslie, Royal United Hospitals NHS Foundation Trust, Bath,Emily Johnson, Worcester Acute Hospitals NHS Trust, Worcester,Alex Goodwin, Royal United Hospitals NHS Foundation Trust, Bath,Samuel Nava, Severn Deanery, Bristol
Chapter 2.7 explores anticonvulsant drugs. This includes a segment on benzodiazepines commonly used for sedation and anaesthesia, their mechanism of action, uses, side effects and actions in overdose. We then discuss specific antiepileptic agents in detail and the management of status epilepticus.
Hypertension disorders of pregnancy are a clinical spectrum that includes gestational hypertension, preeclampsia, and eclampsia. Hypertensive disorders are a common cause of significant maternal and fetal morbidity and mortality. Therefore, it is important for women’s health clinicians to be knowledgeable of the diagnostic criteria and management guidelines. A 25-year-old gravida 3 para 0 at 35 weeks’ gestation presents with a blood pressure of 165/95, proteinuria, and develops seizures. Based on her clinical presentation, physical examination, and laboratory findings, a diagnosis of eclampsia was made. The patient was promptly stabilized, treated with magnesium sulfate for seizure prophylaxis, received antihypertensive treatment, and delivered in a timely manner. The case highlights the recommended maternal evaluation, fetal surveillance, timing of delivery, and treatment for hypertension disorders of pregnancy.
Levetiracetam (LEV) is an antiseizure medication (ASM) used as a second line after benzodiazepines for status epilepticus treatment. Current literature lacks direct head-to-head comparisons between different LEV loading dose strategies, leading to uncertainty about superior dosing methods and thus clinical practice variations.
Methods:
A retrospective cohort study was designed to compare efficacy and safety of low (<30 mg/kg) versus high (≥30 mg/kg) weight-based LEV loading doses in adults with benzodiazepine-refractory status epilepticus (BRSE). The primary outcome of this study was termination of BRSE. No requirement for additional ASM after LEV was a surrogate for BRSE termination. Secondary endpoints included endotracheal intubation, intensive care unit (ICU) admission, 30-day all-cause mortality and adverse drug reactions. Statistical analysis included discrete and inferential statistics, including logistic regression and win-ratio analysis, to control for potential confounding variables.
Results:
Of the 106 patients included in this study, 54 (51%) did not require additional ASM after LEV, thereby achieving seizure termination. There was a higher proportion of patients with seizure termination in the higher weight-based dosing group as compared to the lower weight-based group (66% vs 40%, respectively; aOR 3.07; 95% CI: 1.36–7.21). There were lower rates for endotracheal intubation, ICU admission and all-cause mortality in the higher dosing group. Adverse events were comparable between the both groups.
Conclusion:
LEV’s high weight-based loading dose strategy (≥30 mg/kg) is more effective in the termination of BRSE as compared to the lower weight-based loading dose strategy (<30 mg/kg).
Newly emerging US cyberspace warfighting concepts highlight the need to update US legal doctrine. Concepts adapted to future high-intensity, high-paced armed conflict, including command post dispersal and integration of cyberspace into other targeting domains, present opportunities to refine US understandings of the law of war attack threshold and overlooked rules applicable to destruction and seizure. The advantages of staking out clear and current opinio juris on these and other matters extend beyond providing responsible and consistent operational law advice. Updated and authoritative military cyber legal doctrine will serve the strategic and diplomatic legal interests of the United States and the international legal system as a whole.
Epilepsy is one of the most common neurological disorders, affecting people of all ages. This chapter focusses on what has been learnt about the microRNA system in this important disease. Starting with an overview of epilepsy, it addresses what causes seizures to occur and some of the underlying mechanisms, including gene mutations and brain injuries. It explores how and which microRNAs drive complex gene changes that underpin but also oppose the enduring hyperexcitability of the epileptic brain. This includes by regulating amounts of neurotransmitter receptors, structural components of synapses, metabolic processes and inflammation. It also covers some of the earliest studies linking microRNAs to epilepsy as well as recent large-scale efforts to map every microRNA and its target in the epileptic brain. Finally, it highlights ways to model epilepsies and use of experimental tools such as antisense oligonucleotides to understand the contributions of individual microRNAs. Collectively, these studies reveal how microRNAs contribute to the molecular landscape that underlies this disease and offer the exciting possibility of targeting microRNAs to treat genetic and acquired epilepsies.
Shortly after microRNAs were discovered in humans they were found to be present in blood samples. This led to another branch of microRNA research with the potential to transform medicine, answering the question healthcare professionals ask every day. What’s wrong with my patient? This chapter introduces circulating microRNAs as biomarkers and their emergence as potential diagnostic tools. Core arguments in their favour as indicators of health and disease include tissue specificity, their known locations in the body enabling doctors to zero in on where a problem lies. It looks at what shelters microRNAs as they circulate in the bloodstream and the disruptive thinking that has interpreted such findings as evidence that extracellular microRNAs are conveyors of information between distant tissues in the body. It moves to efforts to probe ever-smaller volumes of biofluids to find the least-invasive source of microRNA biomarkers and the diseases for which microRNA-based diagnostic tests already exist or may emerge in the future. Finally, it looks at developments in RNA detection technology that might allow point-of-care testing and perhaps microRNA-based health monitoring at home.
This chapter focuses on several of the most common actionable EEG abnormalities. This includes defining and describing epileptiform discharges, which are abnormal EEG waves that serve as markers of increased seizure risk. This also includes seizures themselves, and their characteristics and electrographic criteria. Prolonged and repetitive seizures known as status epilepticus are described, including their specific electrographic characteristics and criteria. The treatment resistant form of status epilepticus known as refractory status epilepticus is also described. Finally, the chapter describes a high risk electrographic phenomenon known as brief potentially ictal rhythmic discharges (BIRDs).
This chapter focuses on quantitative EEG processing, also known as EEG trend analysis. These types of algorithms process raw EEG data in a quantitative way, and display the data in more compressed forms that may be easier for the amateur EEG reader to interpret. Specific QEEG algorithms described in this chapter include amplitude integrated EEG, FFT spectrogram, rhythmicity spectrogram, asymmetry indices, and seizure detectors. Specific roles for QEEG covered include seizure detection and detection of focal cerebral ischemia.
We evaluated the effectiveness and tolerability of brivaracetam (BRV), an adjunctive antiseizure medication, as a treatment for focal epilepsy in adults. In this prospective study, we enrolled 51 participants from 3 sites across Canada. At 6 months, 68% (26/38) of participants were still taking BRV, among whom 35% (8/23) attained seizure freedom and 48% (11/23) saw their seizure frequency reduced by over 50%. We did not measure any significant change in irritability, quality of life, depression, and anxiety while treated with BRV. Our findings suggest BRV is effective in reducing seizure frequency among adults with focal epilepsy.
This chapter examines a key aspect of the worldwide sanctions response: sanctioning individuals personally, including wealthy oligarchs holding vast, often-hidden wealth. This chapter explores how and why certain individuals were sanctioned, like Putin’s daughters and prominent Russian government and business figures. Lesser-known sanctioned figures are also discussed. It also discusses the difficulties of linking assets to sanctioned individuals once wealth is laundered and converted into certain types of assets. The chapter discusses measures taken by various jurisdictions to improve the effectiveness of sanctions by promoting financial transparency.
This chapter reviews how the recent sanctions have been enforced, both by domestic authorities and through multilateral cooperation. chapter also examines strategies taken by would-be sanctions evaders to conceal their attempts to circumvent the broad sanctions. Enforcement plays a key role in the ability of the sanctioning jurisdictions to effectively implement their sanctions and incentivize change in the behavior of the target or by parties indirectly affected by the sanctions.